Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

reMARK-AML

Financiado

Re-envisioning risk biomarkers in acute myeloid leukemia (AML) at single-cell le...

Re-envisioning risk biomarkers in acute myeloid leukemia (AML) at single-cell level Acute myeloid leukemia (AML) is one of the most aggressive, clinically and biologically heterogenenous, hematological alignancies. The different genetics classify disease entities, and define the prognostic risk category to which... ver más

31/01/2025

UNIPG

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

UNIVERSITA DEGLI STUDI DI PERUGIA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-07-17

ERC-2023-POC: ERC PROOF OF CONCEPT GRANTS Objective:Objectives:The ERC Proof of Concept Grants aim at facilitating exploration of the commerci...

I+D

Cerrada hace 1 año

0% 100% 100%

1 Participantes

UNIPG

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2012-35342 BUSQUEDA DE NUEVAS DIANAS TERAPEUTICAS EN LEUCEMIA MIELOIDE... 117K€ Cerrado

SAF2016-75442-R GENERACION DE NOVO DE LEUCEMIA T LINFOBLASTICA AGUDA (T-ALL)... 290K€ Cerrado

PID2020-117645RA-I00 IMPACTO FUNCIONAL DE LAS MUTACIONES NO CODIFICANTES ASOCIADA... 206K€ Cerrado

SAF2015-66986-R EVALUACION DE BMP4 COMO BIOMARCADOR EN EL PRONOSTICO DE LA L... 121K€ Cerrado

PDC2022-133488-I00 NUEVO FARMACO REGULADOR DE NPM1 PARA EL TRATAMIENTO DE LA LE... 146K€ Cerrado

CNS2023-144908 Biología molecular y celular 400K€ Cerrado

Duración del proyecto: 18 meses Fecha Inicio: 2023-07-17
Fecha Fin: 2025-01-31

Líder del proyecto

UNIVERSITA DEGLI STUDI DI PERUGIA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Acute myeloid leukemia (AML) is one of the most aggressive, clinically and biologically heterogenenous, hematological alignancies. The different genetics classify disease entities, and define the prognostic risk category to which AML patients are assigned and the treatment choices.There is one entity, the AML with nucleophosmin (NPM1) gene mutations, that accounts for onethird of all adult AML (the most frequent) and where another gene mutation - the Fms-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) - acts as ‘tip of the balance’ for patients’ risk definition, drastically worsening the prognosis and hanging treatment in those 40% of patients where it is detected. This has been a main field of research of Prof. Maria Paola Martelli and her team since years and specifically of her ERC consolidator grant ContraNPM1AML. Here, she will exploit concepts stemming from her ERC funded studies on the key role of kinases in the NPM1-mutated AML development, response to therapy and initiating relapse, and focus on that 60% of patients regarded at favorable prognosis, who nevertheless in 40% of cases will relapse with extremely dismal outcome. Currently, successful strategies to identify novel frontline key markers to refine risk are not available. reMARK-AML takes the challenge and changes prognostic risk parameters, pointing at re-envisioning the marker at single-cell level. A first strategy has been designed and will be tested for the proof-of-concept in patients in a prospective non-interventional study. We have established contacts with industrial partners for the development of fit-for-purpose diagnostic assay prototypes to test then in the study. The success of reMARK-AML will open the next challenge of developing marketable diagnostic kits and defining a strong business plan in order to measure the impact of our idea and PoC in the real-world clinical setting.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores